Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.

Duvakitug demonstrated a significant endoscopic response in 48% of patients with Crohn's disease, with the 900 mg dose exceeding placebo response rates in a phase 2b trial.

• Why it matters: Crohn's disease remains challenging to treat effectively, especially in patients who do not respond to existing therapies, highlighting the need for new targeted treatments with proven efficacy and safety.
• What they did: A multicentre, randomized, placebo-controlled phase 2b trial enrolled 139 adults with active Crohn's disease, comparing two doses of duvakitug (450 mg and 900 mg) against placebo, assessing endoscopic response at week 14.
• The result: The 900 mg dose achieved a 33% higher response rate than placebo with high probability of superiority, and no safety concerns emerged, supporting further development of duvakitug as a potential therapy.